Compare Franco-Nevada Corporation (FNV) vs Halozyme Therapeutics Inc. Common Stock (HALO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franco-Nevada Corporation vs Halozyme Therapeutics Inc. Common Stock — how do they compare? Franco-Nevada Corporation trades at $233.84 (market cap $46.80B), while Halozyme Therapeutics Inc. Common Stock trades at $117.19 (market cap $12.44B). The key difference: Franco-Nevada Corporation is far larger — about 3.8× Halozyme Therapeutics Inc. Common Stock's market cap, and Franco-Nevada Corporation pays a 0.72% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Franco-Nevada Corporation for 0 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| FNV | HALO | |
|---|---|---|
Market Cap | $46.80B | $12.44B |
Volume | 310,692 | 1,772,623 |
Sector | Basic Materials | Health |
52-Week High | $280.82 | $116.82 |
52-Week Low | $183.97 | $61.63 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $45.79B | $14.36B |
Dividend Yield | 0.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Franco-Nevada (FNV) trades at $243.85, showing a slight decline of 0.77% over the past day. The stock is positioned neutrally from a technical perspective, with key support near $242 and resistance at $246. Fundamentally, the company exhibits strong profitability with a net income margin of 63.79% and has beaten earnings expectations in two of the last three quarters. Recent news highlights portfolio expansion, including a significant investment in the Bullabulling Gold Project and positive developments regarding the potential restart of the Cobre Panama mine.
The outlook for FNV is supported by analyst consensus, with a price target of $275 suggesting potential upside. Key opportunities include revenue growth from new projects and high profit margins. Risks involve execution on new investments, commodity price volatility, and geopolitical factors affecting mining operations. The balanced analyst rating split indicates cautious optimism for future performance.
Halozyme Therapeutics (HALO) trades at $109.62, down 1.31% today but near its recent highs. The stock shows strong fundamental momentum with revenue growth from $1.4B in 2025 to $1.7B projected for 2026 and net income margins improving to 24.85%. Recent positive developments include a patent win against Merck in Europe and an expanded collaboration with argenx, enhancing its ENHANZE technology revenue streams. Technical indicators are bullish on moving averages, though oscillators signal neutrality with RSI at 73 suggesting overbought conditions. Support is firm at $107 with resistance at $112.
HALO presents a growth opportunity driven by robust financials and strategic expansions, but risks include high valuation multiples (P/E 32.15, P/B 86.68) and insider selling by the CEO. Analyst consensus is strongly bullish with 66.7% buy ratings and a $106 price target, though the current price exceeds this, indicating potential near-term consolidation. Investors should weigh solid earnings beats against elevated expectations and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Franco-Nevada Corporation
Franco-Nevada Corporation is a royalty and streaming company that finances mining and energy projects in exchange for royalty payments or the right to purchase output at set prices, holding a diversified portfolio across Precious Metals, Other Mining, and Energy (oil, gas, and natural gas liquids).
Read more on FNV →About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →
